W F Benedict
Overview
Explore the profile of W F Benedict including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
2939
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benedict W, Fisher M, Zhang X, Yang Z, Munsell M, Dinney C
Cancer Gene Ther
. 2014 Feb;
21(3):91-4.
PMID: 24503570
A phase l study using intravesical Ad-IFNαSyn3 for patients with bacillus Calmette-Guérin-resistant superficial bladder cancer showed a complete remission (CR) of 43% at 90 days after treatment with high levels...
2.
Yang Z, Zhang X, Dinney C, Benedict W
Cancer Gene Ther
. 2011 Jun;
18(9):609-16.
PMID: 21681220
Over the past several years we have obtained considerable evidence indicating that adenoviruses-expressing interferon α (Ad-IFNα) can overcome resistance to the IFNα protein itself. Since cancer cells infected with Ad-IFNα...
3.
Zhang X, Yang Z, Benedict W
Cancer Gene Ther
. 2010 Dec;
18(4):260-4.
PMID: 21183949
We have previously shown that adenoviral-mediated interferon α (Ad-IFNα) is cytotoxic both to cells that are sensitive to recombinant interferon α (IFNα) and to cells which are resistant to IFNα....
4.
Zhang X, Dunner Jr K, Benedict W
Cancer Gene Ther
. 2010 May;
17(8):579-84.
PMID: 20489789
We have previously shown that adenoviral-mediated interferon alpha (Ad-IFNalpha) treatment is highly cytotoxic to tumor cells which are resistant to the IFNalpha protein. We now report that autophagy is produced...
5.
6.
Fisher M, Zhang X, McConkey D, Benedict W
Cancer Gene Ther
. 2009 Feb;
16(7):567-72.
PMID: 19197325
Adenoviral transduction of human bladder cancer cells with human interferon alpha-2b (Ad-IFN) produces cancer-specific cell death through direct and indirect mechanisms. The indirect mechanisms involve the secreted IFN produced, which...
7.
Zhou J, Zhang X, Ashoori F, McConkey D, Knowles M, Dong L, et al.
Cancer Gene Ther
. 2008 Jul;
16(1):13-9.
PMID: 18654611
RB94, which lacks the N-terminal 112 amino-acid residues of the full-length retinoblastoma protein (RB110) is a more potent inhibitor of cancer cell growth than RB110, being cytotoxic to all cancer...
8.
Zhang X, Dong L, Chapman E, Benedict W
Cancer Gene Ther
. 2008 Jul;
15(12):817-22.
PMID: 18617914
We have reported earlier that a bystander effect is seen in cancer cells that are resistant to high concentrations of the interferon-alpha protein (Intron A) when treated with adenoviral-mediated interferon-alpha...
9.
Nagabhushan T, Maneval D, Benedict W, Wen S, Ihnat P, Engler H, et al.
Cytokine Growth Factor Rev
. 2007 Aug;
18(5-6):389-94.
PMID: 17692556
Intravesical administration of interferon alpha-2b protein (IFN) has been successfully used in the treatment of patients with superficial bladder tumors. Local dosing of IFN minimizes well-known systemic side effects of...
10.
Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey D, Benedict W
Cancer Gene Ther
. 2006 Nov;
14(3):241-50.
PMID: 17096027
We have previously shown that intravesical administration of adenovirus encoding human interferon alpha-2b (Ad-IFN) induced a marked regression of superficial human bladder tumors derived from cells that are resistant to...